Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company’s products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and GlucoBreak, a fat-free glucose spray. Generex Biotechnology Corporation’s under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; and morphine and fentanyl products for breakthrough and postoperative pain. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S. The company was founded in 1983 and is based in Toronto, Canada.
This stock has huge potential. Oral-lyn, the insulin spray is going to revolutionize the insulin industry. No more needles. This is a former $25 stock and is only trading at 61 cents, that's a tremendous bargain. If everything goes to plan this stock is going to explode! The sky's the limit.
They took a big step in the right direction with the hiring of Dr. Joseph Rubinfeld as the Company's Chief Scientific Advisor. Rubinfeld was responsible for the development of the multi-billion dollar antibiotic Amoxicillin and has 50 years experience in the industry.
Amgen Co-founder to Act as Generex Chief Scientific Advisor (Nasdaq:GNBT)
This stock is definitely worth a look. I'm in a 48 cents and holding on for the ride. |